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ABSTRACT 
 
Human neutrophil specific antigen CD177 plays a role in various clinical 
and immunological syndrome such as immune mediated neutropenia, transfusion 
related acute lung injury (TRALI) and polycythemia rubra vera (PRV). Recently, 
strong upregulation of CD177 was observed during bacterial infection and sepsis. 
Although the clinical importance of CD177 has been studied for nearly three 
decades, not much is known about the function of CD177 on neutrophils. Strong 
upregulation of CD177 noted during bacterial infection and sepsis.  
To study the possible role of CD177 in the first step of the inflammation process, 
we sought to determine the counter receptor of CD177 on endothelium. For this 
purpose, we first produced CD177-Fc fusion protein in insect cells to capture 
endothelial CD177 counter receptor. Immunofluorescence analysis showed 
specific binding of CD177-Fc to the human umbilical vein endothelial cell 
(HUVEC). Immunoprecipitation of biotin surface labeled HUVEC with CD177-Fc 
protein yielded a specific band of 130 kDa. By use of a panel of monoclonal 
antibodies in immunoblotting experiment, we could identify this band as platelet 
endothelial cell adhesion molecule-1 (PECAM-1). This result could be confirmed 
by real-time protein-protein analysis using surface plasmon resonance 
technology. Purified PECAM-1 bound to CD177 with a Kd of 8.5*106 in cation-
dependent manner.  Analysis of CD177 transfected cells on PECAM-1 protein 
showed a specific adhesion, which is inhibited by mab against CD177 (clone 
MEM166) as well as mabs specific for PECAM-1 (clones PECAM 1.1 and 1.2). 
Similar findings were observed when the adhesion of human neutrophil 
expressing CD177 on HUVEC was analyzed. 
In summary, we identified endothelial PECAM-1 as the counter receptor of 
neutrophil CD177.  This heterophilic binding opens the new concept of multistep 
interaction between neutrophil and endothelium, as an important process in the 
inflammation. 
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1. INTRODUCTION 
  
             CD177 is belongs to the Ly-6 gene super family, which is  also known as 
the snake toxin family, Ly-6 genes were first described in mice encodes family of 
leukocyte surface glycoproteins expressed by a subpopulation of lymphoid and 
myeloid cells during haematopoiesis from multipotential stem cells to lineage 
committed precursor cells. Proteins encoded by the Ly-6 genes are divided in to 
two subfamilies as one subfamily encodes GPI anchored proteins and the 
second subfamily encodes secretory proteins. The Ly-6 family is characterized by 
the presence of 70-100 conserved amino acids and 8 to 10 cysteine rich 
domains. Human Ly-6 genes encodes the GPI anchored proteins with a one or 
three cysteine rich domains, urokinase plasminogen activator receptor (uPAR) 
and CD59, respectively, are described. uPAR is expressed by neutrophils, 
monocytes and their precursors and serves as a high affinity receptor for 
urokinase plasminogen activator (uPA). uPAR also plays a role in cell migration, 
adhesion and cellular invasion. CD59 or membrane inhibitor of reactive lysis is 
expressed by erythrocytes as well on leukocytes is an important erythrocyte 
membrane molecule that inhibits complement mediated lyses and protects cells 
from membrane attack complex induced lysis. 
 
           Recently, a new member of the Ly-6 gene family, human CD177, has 
been described as a gene located on chromosome 19q13.2, comprised of 9 
exons and an open reading frame of 1311 bp which encodes 437 amino acids 
with an N-terminal signal peptide of 21 amino acids. CD177 consists of two highly 
homologous cysteine rich domains of 188 amino acids each containing 6 
cysteine residues, three potential N-glycosylation sites, and a hydrophobic C-
terminus with a GPI (Glycosyl Phosphatidyl Inositol) anchor. CD177 of 58-64 kDa 
are expressed by neutrophils and their precursors. The CD177 expression is 
unusual as only expressed on subpopulations of neutrophils with the mean size 
of 45-65%. The reason for this phenomenon is unclear. CD177 is polymorphic 
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and comprises of two alleles PRV-1 (polycytemia rubra vera-1) and NB1 
(neutrophil antigen B-1 or termed as Human Neutrophil Antigen-2).  
 
          In the last decade, studies in our group and in others were focused on the 
structure of CD177, polymorphisms, antigen expression and their relevance in 
immune mediated neutropenia and bacterial infections. However, little is known 
about the function of CD177. Preliminary studies indicated that CD177 on 
neutrophils may interact with endothelial cells. In this study, we characterized the 
functional role of CD177 in respect to neutrophil-endothelial cell-cell interaction 
(see Figure 1). The primary objective of this study is to identify CD177 ligand on 
endothelium to gain a hint about the cellular function of CD177.  
 
 
 
Figure 1: Hypothesis of the functional role of CD177 on the adhesion and transmigration process 
of neutrophils through endothelial cells (EC). Rolling,adhesion and transmigration process of 
neutrophils described schematically. The putative CD177 counter-receptor is indicated by 
question mark (?). 
CD177 
?
?EC 
Adhesion
Transmigration 
Rolling
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1.1. REVIEW OF LITERATURE 
 
1.1.1. Neutrophils 
Neutrophils are white blood cells also known as polymorpho nuclear 
leukocytes represent 50 to 60% of the total circulating leukocytes which functions 
as the first line of defense against infectious agents or non self substances that 
penetrate the body’s physical barriers such as bacteria, fungi, protozoa, viruses, 
infected cells and tumors. Neutrophils develop in bone marrow, where they 
undergo proliferation and differentiation which takes about two weeks. 
Neutrophils and macrophages eliminate pathogens via opsonization and kill them 
by proteolytic enzymes and reactive oxygen species (Kobayashi et al 2005; Boos 
et al 2006). Under normal conditions neutrophils roll along vascular walls, but 
during inflammatory conditions neutrophils can adhere, penetrate the endothelial 
monolayer and migrate through connective tissues to sites of infection along the 
chemotactic gradient. 
Neutrophil extravasation is a multistep process comprising of rolling, adhesion 
and transendothelial migration (Figure 2). Rolling is mediated by E- and P-
selectins (endothelial and platelet selectins) on endothelial cells, which bind to 
selectin ligand (PSGL) on neutrophils. This process is then followed by adhesion 
of neutrophils, which involves the additional binding of integrins on neutrophils 
(α2-integrins) to the Ig-like molecules on endothelial cells (ICAMs). Finally, bound 
neutrophils migrate between the endothelial cells to leave the blood vessels and 
enter the tissue. Neutrophils are then attracted to the injured site by the 
chemokines.   
Specific receptors and counter receptors interactions are involved in the process 
of inflammation (Figure 2). The first step, rolling is mediated by selectins on 
endothelial cell and its counter receptor P-selectin glycoprotein ligand (PSGL). 
This process is then followed by firm adhesion of neutrophils on endothelium by 
interaction between integrins on neutrophils (VLA-4, LFA-1 and Mac-1) to their 
counter receptors on endothelium (e.g VCAM-1, ICAM-1) (Davenpeck et al 2000; 
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Albelda et al, 1994; Bevilacqua, 1993). The next crucial step is transendothelial 
migration of neutrophils is not well understood. One of the most important 
molecule is PECAM-1, which is expressed on both neutrophils and endothelial 
cells (Albelda et al, 1991; Newman et al, 1992). In addition, another cell adhesion 
molecule, CD99 plays a role in neutrophil transendothelial migration (Allport et al, 
1997; Cooper et al, 1995). 
Recently, our group demonstrated that interaction between αMβ2 integrin (Mac-1) 
on neutrophils and junctional adhesion molecule-C (JAM-C) is important for the 
first step of neutrophil migration through endothelial cells (Santoso et al, 2002; 
Chavakis et al, 2004). 
Recently, a member of the JAM family is known to interact in both homophilic and 
heterophilic manner (Keiper et al, 2005). Therefore, it is obvious to presume that 
endothelial PECAM-1 might also serves as a heterophilic ligand for neutrophil 
receptor(s). At the last stage of neutrophil transmigration through tight junctions, 
PECAM-1 dependent transmigration may then follow by VE-cadherin assisted 
diapedesis.  
Several sources of evidence demonstrated that PECAM-1 on endothelial cells 
play an important role in transendothelial migration of monocytes. However, little 
is known about its role in neutrophil transmigration (Wakelin et al, 1996; Albelda 
et al, 1994).   
In the next chapter 1.1.6 the role of PECAM-1 in neutrophil transmigration will be 
discussed in detail. 
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Figure 2: Overview of receptors and counter receptors involved in neutrophil extravasation. 
ESGL-1-E-selectin glycoprotein ligand-1, ICAM-1: Inter cellular adhesion molecule-1, VCAM-1: 
Vascular endothelial cell adhesion molecule-1, Mac-1:CD11b/CD18; alpha (M) Beta (2), LFA-1: 
CD11a/CD18; Lymphocyte function associated antigen-1, VLA-4: CD49d/CD29; very late 
antigen-4, JAM-C: Junctional adhesion molecule-C, CD99: Glycoprotein expressed on 
leukocytes. CD177: Human neutrophil antigen 2, PECAM-1; platelet endothelial cell adhesion 
molecule-1. 
 
1.1.2. CD177  
 
Cellular distribution 
CD177 is only found on neutrophils but not on other blood cells 
(Goldschmeding et al, 1991). The expression of CD177 on the neutrophil surface 
is unique. In 97% of our population, CD177 are detectable on the cell’s surface, 
but the expression, however, is heterogeneous. In one individual, CD177 
negative as well as CD177 positive neutrophil populations could be observed. 
The reason for this heterogeneity is not yet known. Single nucleotide 
polymorphisms of CD177 seem to be associated with an increase in the size of 
the neutrophil population. Our group and others have found that the G42C 
ICAM-1 VCAM-1 
JAM-C 
PECAM-1 
CD99 
LFA-1 VLA-4 
E-Selectin 
ESGL-1 
Rolling 
Adhesion 
Transmigration 
Endothelium 
VE-Cadherin 
CD 
177 
 Mac-1 
PECAM-1 
Mac-1 
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dimorphism of CD177 was associated with the size of the neutrophil population 
expressing CD177 (Wolff et al, 2003; Carruccio et al, 2004).   
 
Recent data from in vivo studies showed that stimulation of neutrophils with 
granulocyte-colony stimulating factor (G-CSF) led to the upregulation of CD177 
transcripts (Stroncek et al, 1998). Up regulation in the CD177 gene expression 
was also observed in granulocyte progenitors upon inactivation by estrogen-
dependent form of E2a-Pbx1 oncoprotein (Sykes et al, 2003). Recent analysis on 
neutrophils collected from women both early and late in pregnancy showed that 
the expression of CD177 antigen increases during the pregnancy (Carrucio et al, 
2003). All these observations indicated that besides gene polymorphisms the 
variability in neutrophil expression of CD177 among individuals may also cause 
by differences in gene regulation or in post-translational protein modification.  
 
In rare cases, individuals lacking CD177 were described approximately as 3% of 
Caucasians, 5% of African American and 11% of Japanese having CD177 
deficient neutrophils (Matsuo et al, 2000; Stroncek et al, 2004). One of the 
causes of this deficiency is mRNA splicing defect (Kiessel et al, 2002). Elevated 
levels of CD177 transcript in neutrophils were recently found in patients with 
bacterial infections, but not in patients with viral hepatitis (Gohring et al, 2004) 
 
Molecular nature of CD177 
CD177 is a GPI linked membrane protein with a molecular mass of 54-68 
KDa. CD177 glycoprotein consists of 437 amino acids with a signal peptide of 21 
residues, two cysteine rich domains (residues 133-210 ; 325-399), three potential 
N-linked glycosylation sites and short transmembrane and cytoplasmic segments 
including a GPI attachment site (Kiessel et al, 2001). 
CD177 is polymorphic in human and comprises of two alleles, NB1 (neutrophil 
antigen B-1 or termed as Human Neutrophil Antigen-2) and PRV-1 (polycytemia 
rubra vera-1). The most common allele of CD177 is PRV-1 (Termeniac et al, 
2000). The NB1 allele differ only 4 nucleotides (G42C, C390T, G1003A and 
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T1171C) that result in four amino acid exchanges (Ala3Pro, Leu119Phe, 
Arg323Gln and Phe379Ser) (Kiessel et al, 2002; Bettinoti et al, 2002). In addition, 
immediately adjacent to CD177 is a pseudogene that is highly homologous to 
exons 4 through 9 of CD177 in tail to head orientation (Bettinoti et al, 2002). 
 
Alloimmunization against neutrophil specific antigen, NB1, has been described 
three decades ago by Lalezari et al (1971) in a case of alloimmune mediated 
neutropenia. For the systematic naming of neutrophil antigens a new 
nomenclature for human neutrophil alloantigens (HNA) was introduced. This 
nomenclature is based on the antigen glycoprotein location (Table 1). To date, 
five different glycoproteins are known as carriers of antigenic determinants on 
neutrophils. The first alloantigen comprises three polymorphic isoforms, HNA-1a, 
HNA-lb and HNA-1c, are localized on FcγIIIb (CD16b). NB1 was renamed as 
HNA-2a. The HNA-3a, -4a and -5a are located on a 70-95 kDa glycoprotein, 
CD11b and CD11a integrin, respectively (Bux et al, 2002)   
 
ANTIGEN SYSTEM ANTIGEN LOCATION FORMER NAME ALLELES 
HNA-1 HNA1a 
HNA-1b 
HNA-1c 
FcγRIIIb 
 
NA1 
NA2 
SH 
FCGR3B*1 
FCGR3B*2 
FCGR3B*3 
HNA-2 HNA-2a CD177 CD177 CD177*1 
HNA-3  HNA-3a 70-95 kDa 5b Not defined. 
HNA-4 HNA-4a CD11b Mart CD11b*1 
HNA-5 HNA-5a CD11a Ond CD11a*1 
 
Table 1: Nomenclature of human neutrophil antigens (HNAs) adapted from Stroncek et al, 2004.  
Illustration of antigen location and alleles depicting glycoprotein polymorphism.  
 
1.1.3. Clinical aspects of CD177 
The human neutrophil antigen CD177 plays an important role in several immune-
mediated disorders such as autoimmune neutropenia, alloimmune neutropenia, 
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febrile transfusion reactions, and also transfusion-associated lung injury, TRALI 
(Stroncek et al, 2002). In the pathogenesis of TRALI, neutrophil-specific 
antibodies as well as HLA antibodies in the plasma of both blood donors and 
receipients have been implicated. The final pathway of the pathogenic 
mechanism of TRALI is increased pulmonary capillary permeability, which results 
in movement of plasma into the alveolar space causing pulmonary edema. 
Currently, TRALI is the leading cause of transfusion-associated mortality, 
(Roberts et al, 2004).  
Several approaches were discussed today to prevent TRALI, including  leukocyte 
reduction, shortening of red cells, platelets storage times, use of detergent 
treated plasma as well as donor selection in respect to neutrophil alloantibodies 
(Sachs et al, 2006). 
 
Several studies have demonstrated an over expression of neutrophil CD177 
transcript in patients with Polycythemia Rubra Vera (PRV), and two other 
myeloproliferative disorders, essential thrombocythemia (ET) and idiopathic 
myelofibrosis (IMF) (Stroncek et al, 2004). Myeloproliferative disorders are 
heterogeneous diseases that occur at the level of a multipotent hematopoietic 
stem cell. They are characterized by increased blood cell production related to 
cytokine hypersensitivity and virtually normal cell maturation. Recently, a unique 
mutation in JAK2 (V617F) was found in patients with PRV, ET and IMF. This 
mutation is located in the JH2 domain (pseudokinase autoinhibitory domain) 
resulting in constitutive kinase activity and induces cytokine hypersensitivity or 
independence of factor-dependent cell lines (Vainchenker & Constantinescu, 
2005). 
 
1.1.4. Function of CD177 
One study suggests that CD177 may play a role in the adhesion of neutrophils to 
endothelial cells (Stroncek et al, 1994). Analysis of neutrophil endothelial 
interaction showed that the adhesion of resting CD177-positive neutrophils is 
lower in comparison to CD177-negative cells. When the neutrophils were 
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stimulated with C5a, PMA, or fMLP, no differences were found in the adhesion of 
CD177-positive and negative cells. Furthermore, no differences were found in 
chemotaxis to C5a, respiratory burst response to PMA, or opsonized zymogen. 
These observations indicated that CD177 may inhibit the adhesion of 
unstimulated neutrophils to endothelial cells. People with CD177 deficient 
neutrophils are healthy indicating that the function of CD177 may be duplicated 
by another protein. However, only few CD177 deficient individuals have been 
studied to determine if the lack of CD177 has a subtle effect on neutrophil counts, 
neutrophil function, host defense, or host response to inflammation. 
 
Recently, Mnjoyan et al (2005) described that CD177 transfected cells grew 
faster than non transfected cells. Even after 5 days of exposure to serum-free 
media, cells expressing CD177 continue to proliferate, whereas the control cells 
ceased.  
 
1.1.5. Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1; CD31). 
PECAM-1 is a member of the immunoglobulin gene super family (IgSF) and has 
an important role in a number of endothelial cell functions including inflammation, 
integrin activation, cell-cell adhesion, angiogenesis and wound healing. PECAM1 
is a 130 kDa glycoprotein that is expressed on the surface of circulating platelets, 
monocytes, neutrophils, T cell subsets and is a major constituent of endothelial 
cells (>106 molecules/cell), but PECAM-1 is not present on fibroblasts, 
epithelium, muscle or other nonvascular cells (for review see Newman & 
Newman, 2006).  
PECAM-1 is encoded by a 75-kb gene that resides at the end of the long arm of 
chromosome 17 and is comprised of 16 exons. The 574 amino acids that 
comprise the extra cellular portion of this molecule are organized into six Ig-like 
homology domains encoded by exons 2-8, a short transmembrane domain and a 
long cytoplasmic domain containing 118-amino acids. The cytoplasmic domain 
contains at least five serine and tyrosine phophorylation sites. Two consensus 
Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs) centered on tyrosine 
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residues 663 and 686 were found. These ITIMs serve to recruit cytosolic 
signaling molecules (in particular SHP-2) during a variety of cellular activation 
events. The extracellular domain of PECAM-1 mediates PECAM-1/PECAM-1 
homophilic interactions between cells and is responsible for capturing PECAM-1 
at cell-cell junctions. These properties are important in PECAM-1 mediated 
leukocyte transendothelial migration and in maintaining endothelial cell junctional 
integrity.  Analysis with monoclonal antibodies against PECAM-1 showed that the 
N-terminal domain (first and second Ig-like domains) is important for the 
homophilic PECAM-1/PECAM-1 binding (Yan et al, 1995). 
In addition to homophilic interactions, several studies have suggested that 
PECAM-1 may also capable of interacting heterophilically with other components 
of the cell surface which is dependent upon the presence of divalent cations 
(Albelda et al, JCB; 1991; Muller et al, J Exp Med, 1992). The binding regions of 
mabs that blocked PECAM-1 mediated heterophilic interaction were located in 
either in Ig-like domain 2 or Ig-like domain 6. Further analysis by site-directed 
mutagenesis pinpointed that a hexapeptide, CAVNEG, within the Ig-like domain 6 
is important for the heterophilic PECAM-1 interaction (Yan et al, 1995). Two 
ligands, cell surface glycosaminoglycans and αvβ3 integrin, were reported as 
potential counter receptor for heterophilic PECAM-1 interaction (DeLisser et al, 
1993; Piali et al, 1995; Buckley et al, 1996). However, recent studies argue 
whether this interaction of physiological importance (Abelda et al, 1991; Sun et 
al, 1996).   
 
1.1.6. Role of PECAM-1 on endothelium 
Early study from Muller et al (1993) described the important role of endothelial 
cell PECAM-1 in mediating transendothelial migration of leukocytes. This process 
involves homophilic interaction between the first extracellular Ig-like domain of 
leukocyte and endothelial cell PECAM-1 (Liao et al, 1997). Futhermore, PECAM-
1 deficient mice exhibit a marked defect in neutrophil and monocyte migration in 
response to inflammatory stimuli (Schenkel et al, 2004). The reason for this is not 
clear yet. Recent study suggests that the primary function of endothelial PECAM-
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1 in the transmigration process is to serve as a passive ligand for leukocyte 
PECAM-1. Homophilic interaction between PECAM-1 on leukocyte and PECAM-
1 on endothelial cell sends activation signal into the leukocyte that upregulate 
integrin function and facilitate the latter stages of transendothelial migration 
(Dangerfield et al, 2002). Treatment with anti-PECAM-1 monoclonal antibodies 
inhibits leukocyte transendothelial migration by blocking their transit through the 
basement membrane (collagen- and laminin-rich barrier). This transit requires 
activated leukocyte integrins (Liao et al, 1995; Thompson et al, 2000). In addition, 
studies with PECAM-1 deficient mice showed that leukocytes from these mice 
became transiently delayed while transversing the perivascular basement 
membrane indicating the involvement of PECAM-1 in modulation of integrin 
function (Duncan et al, 1999; Thompson et al, 2001). 
 
1.1.7. Role of PECAM-1 on neutrophils 
 
  Although neutrophils carry PECAM-1 on the cell surface, little is known 
about its function. During inflammation, neutrophils migrate from the vascular 
lumen into the extravascular sites. Both, in vitro and in vivo experiments have 
suggested that PECAM-1 is required for the transmigration of neutrophils across 
endothelial monolayers (Vaporciyan et al, 1993; Bogen et al 1994; Muller et al, 
1995). Using an in vitro model of leukocyte transendothelial migration, Muller et 
al (1995) demonstrated that the treatment of either leukocytes or the endothelial 
monolayer with soluble PECAM-1 or mabs against PECAM-1 blocked leukocyte 
transmigration without affecting adhesion. These results could be confirmed by in 
vivo experiments in a murine model of peritonitis and in murine model for 
studying leukocyte-endothelial interactions involving the human vasculature 
(Christofidou-Solomidou et al, 1997). In addition, the authors demonstrated that 
extravasated neutrophils displayed decreased surface expression of PECAM-1, 
possibly as result of engagement of its ligand. 
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Berman and coworkers (1995, 1996) observed that the ligation of PECAM-1 on 
monocytes and neutrophils increases the binding capacity of integrin 
CD11b/CD18 (Mac-1). This integrin activation is critical for the transmigration of 
neutrophils at sites of inflammation. Homophilic PECAM-1 interaction regulates 
integrin mediated adhesion (Buckley et al 1998, Tanaka et al 1992) as well as 
other heterophilic cell adhesion by enhancing the expression of heterophilic 
receptors as in the case of αvβ3 (Dangerfield et al 2002). 
Recent data showed that endothelial PECAM-1 functions as a passive 
homophilic ligand for neutrophilic PECAM-1, which after engagement leads to 
neutrophil signal transduction, integrin activation, and transmigration in a 
stimulus-specific manner. Whereas IL-1β elicit PECAM-1 dependent signalling, 
IL-8 mediated transmigration is PECAM-1 independent (O’Brien et al, 2003). 
Recently, Dangerfield et al (2002, 2005) reported the role of integrin α6β1 
upregulation in neutrophil migration through the perivascular membrane, which 
appears to be associated with PECAM-1 engagement. In in vivo murine model, 
blockade of α6β1 inhibits neutrophil migration induces by IL-1β, but not TNFα. 
   
Study in PECAM-1 deficient mice showed that PECAM-/- neutrophils are much 
less polarized and spreading in response to IL-8 gradient, indicating that 
PECAM-1 on neutrophils has a major role in modulating neutrophil-directed 
migration (Wu et al 2005). Comparison of eosinophils, neutrophils and monocyte 
transendothelial migration in vivo showed that neutrophil and monocyte tissue 
recruitment is PECAM-1 dependent, whereas eosinophils tissue recruitment 
seems to be PECAM-1 independent (Miller et al, 2001). 
  
Furthermore, antibody mediated ligation of PECAM-1 enhances the cell adhesion 
of neutrophils onto human dermal microvascular endothelial, which supports the 
fact that PECAM-1 may activate other adhesive protein(s) or complex cascade in 
cis manner. Furthermore, antibody engagement of PECAM-1 on suspended 
neutrophils triggered a prompt intracellular Ca++ signal leads to changes in the 
neutrophil cytoskeleton activity (Kuwabara et al 1992, Elias et al 1998).  
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2. MATERIALS AND METHODS 
 
All chemical and reagents are purchased in Germany unless otherwise 
mentioned. 
 
2.1. Materials 
 
Antibiotics and drugs 
DEPC (Di Ethyl Pyro Carbonate)             Sigma 
Gentamycin                PAN Biotech 
Penicillin / Streptomycin              PAN Biotech  
Protease Inhibitor-Cocktail              Roche 
Trypsin/EDTA               PAN Biotech 
 
Chemicals and reagents 
Ammonium persulfate              Sigma 
Acrylamide/bisacrylamide                                             Roth  
Agarose ultra pure               Roth 
Ammonium persulfate (APS)             Serva 
Ampicillin                Roche 
Boric acid                          Sigma 
Calcium chloride               Sigma 
Coomassie-brilliant-blue R 250             Sigma 
Beta-mercaptoethanol              Sigma 
Bromophenol blue               Merck  
Bovine Serum Albumin (BSA)                                Serva 
Chloroform                Roth 
Ethanol                   Riedel-de-Haen 
Dimethylsulfoxid (DMSO)              Sigma-Aldrich  
Dithiothreitol (DTT)               Sigma-Aldrich 
Dextran                                                                         Amersham Pharmacia  
Disodium Hydrogen phosphate (Na2HPO4)                  Merck 
Ethanol (100%)                         Roth 
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Ethylenediamine tetraacetic acid (EDTA)           Merck 
Fetal bovine serum                                    Bio west  
Formaldehyde               Sigma 
Ficoll                                                                              Amersham Pharmacia 
Glycerol                Sigma-Aldrich 
Glacial acetic acid               Sigma 
Hydrogen peroxide               Merck  
Isopropanol                Merck 
L-Glutamine                PAN biotech 
Methanol                Roth 
NHS-LC Biotin                                                              Amersham Pharmacia                             
Paraformaldehyde               Sigma 
Penicillin/Streptomycin                         Merck 
Ponceau-S red               Serva 
Protein-A beads                                                            Amersham Bios, Sweden 
Protein-G beads                                                            Amersham Bios, Sweden 
Rotiphorese Gel 30               Roth   
Sodium acetate               Merck 
Sodium dodecyl sulfate (SDS)             Sigma-Aldrich 
Sodium pyrophosphate               Aldrich 
Sodium ethylenediamine tetraacetic acid                     Sigma-Aldrich   
Sodium sulphide                                                           Merck   
Sodium dihydrogen phosphate                        Merck   
Sodium chloride                Riedel-de Haen 
Trypsin                Sigma 
Tetra-methylethylenediamine (TEMED)            Serva 
Tris base                Sigma-Aldrich 
Tris (hydroxymethyl)aminomethane            Sigma 
Triton X-100                Merck 
Tween 20                                                                 Merck 
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Markers 
DNA ladder                                  Cell Signaling, USA 
Rainbow TM protein molecular weight           Amersham Biosciences 
   
Kits 
BCA Protein Assay kit              Pierce, U.S.A 
ECL western blotting kit                                         Amersham Biosciences 
Plasmid mini preparation kit                                        Amersham Bioscience 
 
Materials for cell culture 
Alpha-MEM                                                                 Gibco, USA 
Dulbecco’s Modified Eagle’s medium (DMEM)           Gibco, USA 
Endothelial cell basal medium            PromoCell 
Fetal bovine serum (FBS)             Biochrom KG 
Ficoll-Paque               Amersham 
Gentamycin               PromoCell 
Glutamine                 Promo Cell 
RPMI 1640               Gibco, USA 
Sodium-pyruvate              Gibco, USA 
TNF-α               Roche 
Trypsin-EDTA               Gibco, USA 
Tissue culture dish                Falcon 
Tissue culture flask              Falcon 
Tissue culture 6-well plate                                           Greiner 
 
Antibodies 
Primary antibodies 
Mouse Immunoglobulin (mIgG)                                   Becton Dickinson  
MEM-166                                                                     Serotec 
7D8 (anti-NB1)                        a gift from Dr. D. Stroncek 
PECAM 1.1 (anti PECAM-1)                                        a gift from Dr. PJ Newman 
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PECAM 1.2 (anti-PECAM-1)                                        a gift from Dr. PJ Newman  
Gi18 (anti-PECAM-1)               our group 
Anti-E-selectin                                                               Becton Dickinson 
Anti-P-selectin                                                               Becton Dickinson 
Secondary antibodies 
Rabbit anti-mouse horse radish peroxidase  DPC Biermann 
                                                                                             
Donkey anti-human horse radish peroxidase  DPC Biermann 
                                                                                             
Rabit anti mouse conjugated Fluorescein  DPC Biermann                                               
 
 
2.2. Other materials 
 
BioTrace NT        PALL Life sciences 
Cuvette       Eppendorf 
Filter, sterile 0.45 µm and 0.2 µm    Gelman Science 
Gel blotting paper      Schleicher & Schuell 
Hyperfilm ECL                Amersham Biosciences 
Polyvinylidene fluoride membranes (PVDF)  Millipore, USA 
PVDF membrane      PALL 
Tubes, 15ml type 2095               Falcon 
Tubes, 50 ml type 2070                         Falcon 
X-Ray Flim                AGFA  
X-ray films  X-Omat AR                         Kodak, USA 
Whatman paper (3mm)               Schleicher & Schuell  
 
Instruments 
Blotting-semidry Whattman     Biometra 
Blotting chamber                          Fa. Keutz  
BioDocAnalyzer      Biometra 
BioPhotometer                Eppendorf 
Electrophoresis apparatus                Biorad 
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Centrifuge: RC5C                 Sorvall 
FACS analyser                Becon Dikinson 
Incubator CO2                 Heraeus 
Spectrophotometer       Beckmann 
pH-meter 766      Knick 
Thermoblock                 HLC      
Incubator                 Eppendorf  
Incubator Lab-Thermo     Kühner 
Microscope: light microscope, Type D   Leica Microsystems 
Light Microscope DC 300f     Hund  
ND-1000 UV-Vis Spectrophotometer   Nano Technologies  
 
2.3. Medium 
RPMI medium                                                                PAA      
Supplemented with: 
10% FCS, 0.5% Penicillin/Streptomycin 
 
Optimum medium                                                        PAA   
Supplemented with: 
5% FCS, 0.5% Penicillin/Streptomycin  
 
Alpha-MEM for CHO cells                                           PAA 
Supplemented with: 
10% FCS 
0.5% Penicillin/Streptomycin  
200 µl/ml of Geniticin 
 
Express five SFM medium                                        Invitrogen  
For 200 ml medium 
18 ml of L-Glutamine 
200 µl of Gentamycin  
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500 µl of Blasticidin (1 mg/ml) 
 
Medium for endothelial cells                                  PAA  
For 200 ml of MCDB131 medium 
22.7 ml FCS 
2.3 ml Penicillin/Streptomycin 
2.3 ml L-Glutamine 
909 µl ECGF 
45.5 µl EGF  
 
2.4. Cell lines 
Chinese hamster ovarian cells expressing CD177 
Chinese hamster ovarian cells expressing K1 
Monocytic cell line U937 expressing CD177 
Monocytic cell line U937 
High Five Tricoplusia ni insect derived cells 
 
2.5. Buffers for Protein Chemistry 
Immunoprecipitation buffer 
50mM Tris, 150mM NaCl, 1% Triton X-100 
SDS buffer (2X)  
4% SDS, 15% Glycerol, 62.5mM Tris-HCl pH 6.8, 0.005% Bromophenol blue. 
 
Stripping Buffer 
62.5mM Tris, 2% SDS, 100mM β-mercaptoethanol 
TBS (10x)  
100mM Tris-base, 150mM NaCl adjust the pH to 7.6. 
 
PBS (10X) 
10mM KCl, 10mM NaCl, 16 mM Na2HPO4, 32mM KH2PO4                             
adjust pH to 7.4. 
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Protein lysis Buffer 
50mM Tris, 150mM NaCl, 1% Triton X-100, 2mM PMSF 
 
2.6. SDS-Poly Acrylamide Gel Electrophoresis (SDS-PAGE).  
1.5 M Tris pH 8.8 and pH 6.8 
1.5M Tris and 3M Tris-base adjust the pH to 8.8 or 6.8 with HCl accordingly 
10 x SDS running buffer 
0.1% SDS, 3mM Tris-base, 400mM glycine 
7.5% resolving gel (mini gel)    
2.3 ml of H2O, 1.3 ml of 30% acrylamide, 1.3 ml of 1.5M Tris pH 8.8, 50 µl 10% 
SDS, 50 µl 10% APS, 3 µl TEMED 
5% stacking gel (mini gel) 
1.4 ml H2O, 0.33 ml acrylamide, 0.25 ml of 1.5M Tris pH 6.8, 0.02 ml of 10% 
SDS, 0.02 ml of 10% APS and 2 µl TEMED 
10x TBS 
100mM Tris, 150mM NaCl adjust the pH to 7.6 
 
10x SDS-PAGE-running buffer 
 0.25M Tris, 1.9M glycine, 1% SDS  
 
8x Resolving gel buffer 
3M Tris base, 0.8% SDS and adjust the pH to 8.8  
 
4x Stacking gel buffer 
0.5M Tris base, 0.4% SDS adjust pH to 6.8  
 
Semi dry transfer buffer 
50mM Tris-base, 25mM Glycine, 0.37% SDS, 20 % methanol 
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Blocking buffer 
1.5% BSA in PBS 
 
10xTE buffer 
10mM Tris/HCl, 0.25M EDTA adjust the pH to 7.5.         
10xPBS      
10mM KCl, 10mM NaCl, 16mM Na2HPO4, 32mM KH2PO4 adjust the pH to 7.4  
HBS++ buffer 
20ml of HBS (11x) stock solution 
15mM CaCl2, 15mM MgCl2 
 
2.7. Buffers and solutions used for cell adhesion assay 
 
11xHBS buffer 
 
1.3M NaCl, 44mM KCl, 121mM glucose, 220mM HEPES adjusted the pH to 7.4 
 
 
Adhesion buffer 
 
150mM NaCl, 20mM HEPES, 2mM MgCl2                                          
 
 
Adhesion buffer with MnCl2 and PMA 
 
50mM MnCl2, 50ng/ml PMA                                  
 
Dye Solution 
 
0.5% Crystal violet, 20% Methanol   
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2.8. Experimental methods 
 
2.8.1. CD177Fc construct 
 
The truncated CD177 cDNA fragment encompassing two cysteine-rich 
domains of soluble CD177 fused to human Fc in signal pIg plus expression 
vector was amplified by PCR with forward plasmid primer Kozak (F) 5’-GAG ACC 
CAA GCT TCC TCA GAC ATG-3’ and reverse plasmid primer Kozak (R) 5’-TTT 
ACC CGG AGA CAG GGA GAG GCT-3’ under conditions described in Table 4. 
For CD177-Fc amplification in PCR cycle reaction steps are as follows, 
denaturation of DNA at 95°C for 1min followed by primer anneling at 65°C for 
1min, and polymerisation of DNA strands at 72°C for 2 min with final extension at 
72°C for 8 min, with 32 overall cycles of two and a half hour duration. The PCR 
product of 1996 bp was checked by 1% agarose gel electrophoresis in TBE 
buffer using DNA molecular markers as standard (Biolabs) and then was 
subcloned into pIB/V5-His TOPO Vector by TA cloning strategy (Invitrogen).  
 
Components Concentration Reaction volume 
Sterile water - 25 
Buffer 10x 5 
dNTP 1.25 µM each 8 
Forward Primer 5.0 µM 5 
Reverse Primer 5.0 µM 5 
Taq gold 5U/µl 1 
DNA 1:200 dilution 1 
Total reaction volume - 50 
 
Table 2: PCR mixture for CD177 DNA amplification, table contains a description 
of the components and concentration of PCR mixture.   
 
 
For the ligation, 2µl PCR product encoding for CD177-Fc fusion protein 
was incubated with 1µl pIB/V5-His TOPO Vector, 1 µl of salt solution containing 
1.2 M NaCl and 0.06M MgCl2 and 2µl sterile water for 10 min at room 
temperature and kept on ice. The presence of Topoisomerase-I isolated from 
TOPO vector allows direct ligation of PCR product. Aliquot of 2 µl ligation mixture 
were then transformed into 2 µl one shot TOP 10 competent bacteria. Reaction 
                                                                                                                                                                       
                                                                                                      
29
mixture was mixed gently and incubated on ice for 20 min followed by 30s heat 
shock at 42oC in water bath. After cooling on ice for 1 min, 250 µl of SOC 
medium was added and cells were incubated for 1 h at 37°C. Finally, cells were 
plated to LB Petri dishes containing 100 µg/ml of carbenicillin and were incubated 
overnight at 37°C. For general screening several clones were picked by picking 
half of the colonies and boiled before subjected to PCR (see table 4) to confirm 
the presence of insert. Positive clone was cultured and plasmid DNA was 
isolated using Qiagen miniprep kit.  
The plasmid DNA was inoculated in to 3 ml culture LB medium and grown for 7 h 
to obtain maximum cell density 4.109 cells/ml. Aliquot of 0.9 ml of culture was 
stored with glycerol. The remaining culture medium was spun down for 3000 g at 
4°C for 5 min, and after washing with 5 ml of 10 mM Tris pH 7.5 the pellet was 
resuspended gently in 300 μl of P1 (50 mM Tris-HCl, 10 mM EDTA, pH 8.0). 
Subsequently, 300 μl of P2 (200 mM NaOH, 1% SDS) was added for 5 min 
followed by addition of 300 μl P3 (3.0 M Potassium acetate, pH 5.5) followed by 
15 min centrifugation for 8,000g at RT. Supernatant containing plasmid was 
transferred in to new Eppendorf tube and 595 µl of isopropanol(1/7 vol) added to 
the supernatant at room temperature. After 5 min incubation, plasmid DNA was 
pelleted by centrifugation at 8,000g. Plasmid DNA was then washed with 500 μl 
of 70% ethanol and DNA preparation was resuspended in 30 μl of water and 
stored at 4°C until use. 
To prove the correctness of the insert, plasmid DNA was sequenced using the 
following primers to PIB/V5-His TOPO vector, (Forward: OpIE2 primer 5’- CGC 
ACC GATCTG GTA AAC AC-3’; Reverse: OpIE2 primer 5’-GAG AAT ACA AAC 
TAA GAT TTA GTC AG-3’) and Big Dye 1.3 sequencing reagents. After 
sequencing, the DNA was precipitated by 3M sodium actetate and 100% ethanol, 
washed with 70% ethanol and analyzed on Applied Biosystem.  
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2.8.2. Transfection of CD177-Fc construct into High Five Insect Cells 
 
Aliquots of 1 µl CD177-Fc construct was added to 20 µg of Cellfectin 
reagent in SFM medium. Transfection cocktail was gently mixed for 10 sec, 
incubated at room temperature for 15 min and then added to 60 mm Petri dishes 
containing confluent High Five cells. Transfected cells were incubated for 4 h by 
rocking, which was followed by the addition of 2 ml fresh complete SFM medium. 
Cells were cultured for two to three days and were then selected with 20 µg/ml 
blasticidin. Stable cell lines were cultured in T100 flasks or in triple layered flask 
for scale up and production. Every three days culture supernatants containing 
CD177-Fc fusion protein were harvested and the remaining cells were cultured 
for further production.  
 
2.8.3. Detection of recombinant CD177-Fc by ELISA 
  
Microtiter plates were precoated with 250 ng DAH IgG in coating buffer and 
incubated overnight at 4°C followed by three washes with 0.02% BSA/PBS. 
To prevent non-specific reaction the wells were blocked with 2% BSA for 30 min 
at 4oC. Aliquots of 100 µl CD177-Fc supernatant or 100 ng purified CD177-Fc 
were added and wells were incubated for 1 h at 37°. After washing three times 
with 0.02% BSA, 1 µl of mabs 7D8 or MEM166 (dilution 1:500 in 0.2% BSA) were 
added and incubated for 1 h at 37°C, followed by three washes with 0.02% BSA. 
Bound mabs were detected with 100 µl DAM HRP (dilution 1:8000 in PBS) for 1 
h at 37°C. Excessive mabs were washed away with 0.02% BSA and visualized 
by adding 100 µl OPD and H2O2 as substrate for 1 h at 37°C. Colour reaction 
was stopped by adding 50 µl of 2.5 N sulphuric acid and the reactivity was 
measured at 492 nm in ELISA reader.  
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2.8.4. Purification of recombinant CD177-Fc fusion protein by Protein G 
column 
 
The CD177-Fc fusion protein was purified by affinity chromatography on 
Protein G column which binds specifically the Fc part of CD177. The affinity 
matrix (1ml) was washed in 50 ml of binding buffer packed as column under 
gravity, and equilibrated with the same binding buffer as recommended by the 
manufacturer. The supernatant was loaded on to the column at a low flow rate 
(1ml/min) and washed thoroughly with the same buffer till no detectable protein 
emerged. The bound protein was eluted using glycine or Tris buffer (0.5 M 
glycine HCl, pH 2.9 or 10mM Tris, 150mM NaCl, 30mM Glutathione, 1mM DTT, 
1mM PMSF and 10% glycerol, pH 8.0). Individual fractions were examined for 
the presence of protein and the peak protein fractions were analyzed by 7.5% 
SDS-PAGE and visualized by silver staining. The concentration of purified 
CD177-Fc fusion protein was determined by BCA assay using BSA as standard. 
After incubation at 37°C for 30 min reaction mixture was measured with 
spectrophotometer at 492nm. 
 
2.8.5. Purification of of recombinant CD177-Fc fusion protein by affinity 
column 
 
Sepharose 4B activated column prebound with mab against CD177 was 
washed extensively with 50 ml washing buffer A, 30 ml washing buffer B and 20 
ml washing buffer A. Supernatants containing soluble CD177-Fc fusion protein 
was diluted with binding buffer and passed on to the column at a low flow rate 
(1ml/min), and washed thoroughly with 200 ml of washing buffers A and B until 
no detectable protein emerged from the column. Bound CD177-Fc fusion protein 
was eluted by adding of a 20 ml elution buffer (0.1M citrate buffer, pH 2.0). Small 
fractions were collected and were neutralized with a 1M Tris-HCl buffer, pH 9.5. 
Eluted fractions were pooled and dialyzed against 1xTBS buffer overnight at 4°C, 
followed by the determination of protein concentration.  
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After determining the concentration of CD177-Fc, approximately 20 μg of sample 
was run on 8% SDS PAGE. Separated protein was then fixed for 2 h. Protein Gel 
was washed with H2O to avoid pH changes during development and followed by 
the addition of 0.1% silver solution in 0.2% formaldehyde for 30 min and then 
developed with 2.5% Na2CO3 solution. Staining was stopped by adding 1.5% Di 
sodium-EDTA after 15 min.  
 
2.8.6. Immunoblotting 
For immunoblotting analysis, duplicate protein samples were loaded on to 
10% SDS-PAGE. After the electrophorosis half of the gel was stained with silver 
staining and the other half was transferred to nitrocellulose or PVDF membrane 
using semi dry blotting system. The gel and the membrane were wetted in 
transfer buffer (0.6%Tris, 0.29% Glycine, 0.2% SDS and 20% w/v methanol) and 
protein transfer was done at 0.8 mA/cm2 for 1 hour. The  membrane was stained 
with 0.5% Ponceau-S red, 1% acetic acid solution to assess the quality of the 
transfer and then destained in H2O or washed with 0.1 N NaOH to remove the 
stain completely. 
For immunostaining the membrane was blocked in phosphate buffer 
containing 1.5% BSA for 1h by rocking at room temperature, and then incubated 
with diluted primary antibody ECL-solution (5 μg/ml) containing 1.5% BSA for 1h 
at room temperature.The membrane was washed extensively with ECL-solution 
and incubated with secondary antibody conjugated with horse radish peroxidase 
(rabbit or donkey anti mouse IgG; dilution 1:100000) for 1h at room temperature 
and washed extensively with ECL wash solution. Finally, the blot was developed 
using ECL chemiluminescence substrate and exposed to X-ray film. 
In some cases, blot was reused for further staining after stripping the 
proteins. Membrane bound proteins were treated with glycine pH 2.9 containing  
2% SDS, 100mM β-mercaptoethanol for three times and then washed exten 
sively with ECL buffer. The membrane was then followed by three more 
washings and blocked with 1.5% BSA. For further staining, membrane was 
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stripped (see above) and restained with different mabs against endothelial 
proteins (PECAM-1, E-Selectin and P-Selectin) or against CD177. 
In order to study the binding of CD177-Fc fusion protein with HUVEC, 20 μg (per 
lane) of endothelial cell lysates were loaded on to 10% SDS-PAGE and blotted 
on to PVDF membrane and developed with 5 µg CD177-Fc in (5:2000) . Bound 
CD177 was detected with donkey anti-human IgG at the dilution 1:100000 and 
visualised by incubation with ECL chemiluminescence system. 
 
2.9. Immunoprecipitation with HUVEC 
Washed confluent HUVEC in petridish were surface labeled with 2 ml of 
5mM NHS-LC-BIOTIN for 30 min at room temperature. Excessive biotin was 
removed by washing it three times with 7 ml DPBS. Labelled cells were then 
solubilised with 1 ml of lysis buffer using syringe. Cell lysates were transferred in 
to Eppendorff tube. Cells were incubated on ice for 30 min and vortexing thrice, 
after 30 min centrifugation for 4,000 g at 4°C, supernatant was then transferred 
into a new tube and then stored at –80°C until use. Prior to immunoprecipitation 
lysates were precleared to prevent unspecifc binding. In brief, aliquots of 600 µl 
cell lysates were incubated with 100 µl prewashed Protein G beads together with 
20 μl of normal human serum, 80 μl BSA (100 mg/ml) for 30 min in the rotator at 
room temperature. After centrifugation for 1 min at 1,000 g, preclearing was 
repeated once again. Preadsorbed cell lysates were stored in 100 µl aliquots in -
80°C.  
To 100 μl of prewashed Protein A beads, 2.5 μg of Fc fusion proteins were 
sadded and incubated for 1h on rotator at 4°C. After washing, 300 μl of biotin 
labelled precleared cell lysates were added into the protein coupled beads. 
Mixture was incubated overnight at 4°C on rotator. Beads were then washed five 
times with immunoprecipitaion buffer and then boiled with 2xSDS buffer for 5 min 
at 100°C. Aliquots of 40 μl immunopreciptates were separated on 10% SDS-
PAGE and blotted into nitrocellulose membrane. Membrane was developed with 
HRP labelled streptavidin and visualized using ECL system as described above.  
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2.10. Isolation of endothelial cells from human umbilical cord 
Prior to isolation of endothelial cells, 0.2% of gelatine coated culture 
dishes were incubated at 37°C for 1h. Umbilical cord was cut in one end, and the 
other end was fixed with a needle for two washings of 50 ml of HBS buffer. The 
other end was then closed and it was connected subsequently to three way 
adaptor. 20 ml of collagenase in HBS buffer was injected into the umbilical cord 
and incubated for 20 min in 37°C. The umbilical cord derived EC was fleshed 
with 30 ml of HBS buffer into a tube of 1ml FCS and isolated by centrifugation for 
10 min at 800 g. Isolated HUVEC were re-suspended in 10 ml of MCDB 131 
medium containing 100 μl 1% fungizone and seeded on to culture plates or 
dishes accordingly. 
 
2.10.1. Flow cytometric analysis  
Aliquot of 4.106 HUVEC were fixed with 1% formaldehyde for 5 min and 
then washed twice with PBS. HUVEC were incubated with 4 µg Fc fusion 
proteins (CD177-Fc, PECAM-Fc, or Fc alone as control) for 1h at 37°C. Cells 
were washed with 0.02% BSA in PBS buffer once and then labeled with 40 µl 
FITC conjugated DAH (1:80). After washings, cells were re-suspended in 500 μl 
0.2% BSA for FACS analysis. 
In some cases, binding of CD177-Fc fusion protein to PECAM-1 
transfected cells was performed. Transfected cells or untransfected L-cells (as 
control) were fixed and the procedure was similar as described above.  
 
2.11. ELISA 
To analyse the protein-protein interaction in ELISA, microtiter wells were 
coated with 100 µl DAH IgG (250 ng) overnight at 4°C. Wells were washed 
extensively three times with 0.2% BSA and blocked with 2% BSA for 30 min at 
4°C. Aliquots of 250 ng CD177-Fc fusion protein was added to each well along 
with controls and incubated for 1h at 37°C. After washing it three times with 0.2% 
BSA, 100 ng of PECAM-1 protein was added; alternatively several wells were 
added with 1 μg of EC lysates and incubated for 30 min at 37°C. Bound PECAM-
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1, EC lysate were detected by the addition of mabs Gi18 against PECAM-1 
(1:500 dilution), against E-selectin or against P-selectin at 37°C for 30 min. Wells 
were then washed again for three more times. 100 µl HRP labelled DAM (dilution 
1:8,000) was added for 1h at 37°C. After washings, OPD substrate was added 
and colour development was measured at 492nm in ELISA reader.  
 
2.12. Preparation of purified CD177 and PECAM-1 proteins for SPR analysis   
2.12.1. Isolation of CD177 from granulocytes 
Neutrophils were collected from CD177 positive phenotyped individual 
who was given a pericutaneous injection of Granulocyte Colony Stimulating 
Factor (GCSF-30 μg) for mobilization of neutrophils to blood circulation. After 12 
h, 230 ml of blood was collected and diluted in PBS (1:5). Aliquotes of 15 ml 
blood was layered slowly onto Ficoll gradient and then centrifuged for 20 min at 
800 g. Cell pellets were resuspended into 12 ml of ammonium chloride for 5 min 
on ice to lyse erythrocytes. After washing twice with 50 ml of PBS, approximately 
108 cells of PBS was solubilized in 1 ml lysis buffer (20mM TBS pH 7.4, 0.25% 
Triton-X, 100 μl protease inhibitor cocktail, 100 μl of 5% EDTA) for 30 min. Cell 
lysates were then centrifuged for 30 min at 800 g at 4°C and pooled for 
purification by affinity chromatography using mab 7D8.  
 
2.13. SPR analysis 
CD177 protein-protein interaction with PECAM-1 was examined in real 
time using surface plasmon resonance (SPR) technology on a Biacore 2000 
machine (Biacore AB, Uppsala Sweden). Purified PECAM-1 diluted in 10 mM 
acetate buffer (pH 4.0) in a concentration of 60 μg/ml was directly immobilized on 
to CM5-sensor chip via amino coupling as recommended by the manufacturer. 
Aliquots of 20 μl purified PECAM-1, CD177 or BSA as control was injected at 
different concentrations (0.0–2.0 μM). In some cases, purified CD177 was 
incubated with mabs against different epitopes on CD177 (7D8 or MEM 166) at 
the ratio 1:3 (μM) prior to injection. The running buffer used was PBS (10mM 
sodium phosphate, 150 mM NaCl pH 7.4 containing 0.005% surfactant P20). 
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Sensor chip was regenerated with NaOH (12.5 – 50 mM). Recorded sensograms 
were analysed using BIA evaluation software 3.2 RC1 (Biacore AB). 
Purified PECAM-1 was a generous gift from Dr. P.J. Newman, Milwaukee, USA 
was used to perform SPR assay.  
 
2.14. Cell Adhesion Assay of CD177 transfected U937 cells 
          The monocytic cell line U937 and CD177 transfected U937 cells used in 
this study were generated by the group of Prof. K.T. Preissner (Department of 
Biochemistry, Justus-Liebig University, Giessen). 
Microtiter wells were coated with 500 ng purified PECAM-1 protein in HBS buffer 
overnight at 4°C. Wells were then blocked with 3% BSA in HBS prior to adhesion 
test. Aliquots of 2.105 U937 cells in 50 µl adhesion buffers containing 50 mM 
MnCl2 and 200 ng of PMA were added and cells were allowed to adhere for 1h at 
37° in CO2 incubator. After removing the unbound cells by gentle sucking with 
pump, bound cells were washed twice with 150 μl HBS buffer prior to fixation with 
ice cold methanol for 15 min at 4°C. Cells were then incubated at room 
temperature with 50 μl of crystal violet dye solution. The plate was washed 
extensively with water tub and 100 μl of 50% methanol solution was added to 
measure the colour development at 592 nm. In some cases, transfected cells 
were preincubated with 1μg mabs against CD177 (7D8, MEM 166) or PECAM-1 
(PECAM 1.1, PECAM 1.2 or Gi18).  
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3. RESULTS 
 
3.1. Generation of CD177-Fc construct for expression in insect cells 
 
For the expression of CD177-Fc in insect cells, full-length CD177 in signal pIg 
plus plasmid encoding for soluble CD177-Fc was amplified by PCR using specific 
primers (described in 2.8.1). Amplified PCR product consisting of 1996 bp 
corresponding to CD177-Fc is shown in Figure 3. As a control PCR was run 
without any template. PCR product was then ligated into the PIB-V5 TOPO 
vector for the expression in insect cells. After the ligation and the transformation 
into E. coli bacteria, colonies were screened for insert by PCR using specific 
primers as shown in Figure 6. The presence of the CD177-Fc insert in three 
positive clones could be detected as specific band of 1996 bp. Plasmid from 
positive clone #1 was isolated and purified plasmid DNA was then sequenced for 
verification of the CD177-Fc in PIB-V5 construct (Figure 4).  
DNA sequence analysis using OpIE2 forward and OpE2 reverse primers specific 
for PIB/V5 vector confirmed the presence and orientation of CD177-Fc (panel a) 
and (panel b) in PIB-V5 vector.  
 
 
 
Figure 3: Analysis of CD177-Fc amplified PCR product by Agarose gel electrophoresis. 
PCR amplicon product for CD177-Fc run along with control on 1% Agarose gel. Lane 1: 
molecular marker standard-ΙV, lane 2: control PCR without template; lane 3: amplified CD177-Fc. 
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Figure 4: DNA sequencing analysis of CD177-Fc in PIB-V5 construct. Panel a: Sequencing with 
OpIE2 forward primer demonstrated the right junction between PIB-V5 vector and CD177. Panel 
b: Sequencing with OpIE2 reverse primer showed the right junction between Fc and PIB-V5.  
 
3.2. Characterization of soluble recombinant CD177-Fc fusion protein 
 
Plasmid from clone #1 was scaled up, purified and transfected into Highfive 
insect cells. After transfection stable cells were selected by the use of blasticidin, 
and then screened for the production of soluble recombinant CD177-Fc fusion 
protein in supernatant.  Supernatants were collected after 3 days of culture and 
purified by the use of Protein G column. The purified CD177-Fc protein was 
analysed in ELISA by capturing the Fc part using donkey anti-human IgG coated 
wells. Bound CD177-Fc protein was then detected with mabs specific for CD177 
and enzyme labelled donkey anti-mouse IgG as secondary antibody (Figure 5). 
Positive reactions could be detected with two mabs, 7D8 and MEM166 against 
CD177. In contrast, no reaction was observed with Fc alone as a control. 
Isolation from 1 liter of culture supernatant yielded approximately 400 µg of 
CD177-Fc.  
 
 
Figure 5: Analysis of purified CD177-Fc protein by ELISA. Protein was captured by immobilized 
DAH and then detected with respective monoclonals against CD177, mab 7D8 or MEM166 (3, 5). 
In the control experiments, Fc alone (4, 6) was run in parallel along with negative control PBS (1, 
2) were detected with peroxidase labelled DAM IgG, reaction optical density was measured at 
492nm in ELISA reader. 
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To analyse the purity of CD177-Fc fusion protein SDS-PAGE followed by silver 
staining were performed (Figure 6). Protein corresponding to the expected 
molecular mass (Mr) of 180 kDa for CD177-Fc homodimer was found under 
nonreducing conditions. After reduction of disulfide bond CD177-Fc monomer 
migrates with Mr of 60 kDa.  
 
                       
Figure 6: Analysis of soluble recombinant CD177-Fc protein by 8% SDS-PAGE under non 
reducing condition. After electrophoresis, four different CD177-Fc preparations were silver 
stained (a-lanes 2- 5). Lane 1 represents the molecular marker. b) Reduced form of CD177-Fc  
(b-lanes 1-2) along with molecular marker (b-lane-3).  
 
To test the immunoreactivity of the purified CD177-Fc by the immunoblotting 
experiment, we first performed the immunoblotting experiment with mab against 
a V5 epitope. The CD177-Fc construct was fused with TOPO vector expressing 
V5 protein. As shown in Figure 7, mab anti V5 reacted with CD177-Fc (Mr 180 
KDa), where as staining of Fc alone with this mab yielded a band with Mr of 73 
kDa.  
 
 
Figure 7: Analysis of CD177-Fc and Fc alone in immunblot with anti-V5. Proteins were separated 
on 8% SDS-PAGE, transferred onto nitrocellulose membrane and then stained with mab against 
V5 epitope and visualized using DAM-HRP based ECL detection system.  
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Further more; purified CD177-Fc was tested by the immunoblotting with mabs 
7D8 and MEM166 to confirm the immunoreactivity of CD177. As shown in Figure 
8, purified CD177-Fc protein reacted with both mabs, but not with normal mouse 
IgG as a control.  To confirm the reactivity of the Fc-part, the fusion protein was 
tested in immunoblot using donkey anti-human IgG. As expected, donkey anti-
human IgG was able to detect the CD177-Fc protein with Mr of 180 kDa under 
nonreducing conditions. 
Together, these results demonstrated that the purified CD177-Fc expresses 
immunoreactive CD177 as well as the Fc domain.                                          
 
 
Figure 8: Analysis of purified CD177-Fc by immunoblot using monoclonals against CD177.  
Aliquots of 500 ng protein were run on 8% SDS-PAGE under non reducing conditions and were 
transferred onto PVDF membrane. Proteins were then stained with normal mouse IgG (lane 1), 
mab 7D8 (lane 2), mab MEM 166 (lane 3) and Donkey Anti-Human IgG HRP (lane 4) developed 
with ECL detection system.  
                                                     
3.3. Analysis of CD177-Fc binding to HUVEC by flowcytometry 
 
As evidence from literature (Stroncek et al, 1992) indicates that CD177 may 
interact with endothelial cells, binding analysis was performed with purified 
CD177-Fc and isolated HUVEC from the umbilical cord in flowcytometry. Cells 
were incubated with 4 μg CD177-Fc, Fc, and PECAM-Fc and then visualised with 
fluorescence labelled RAH IgG. Positive staining of HUVEC was observed with 
CD177-Fc, but not with a control Fc. In addition, HUVEC showed also a positive 
reaction with PECAM-1/Fc, which is known as a major protein expressing on 
endothelial cells and interacts to each other in a homophilic manner. This result 
indicates that the counter receptor of CD177 resides on endothelial cells. 
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Figure 9: Analysis of CD177 counter receptor by flow cytometry. Binding of CD177 to endothelial 
cells was demonstrated invitro, isolated HUVEC was stained with Fc alone, CD177-Fc and 
PECAM-Fc. Bound proteins were then stained with FITC labelled Rabbit Anti-Human IgG and 
subjected to flow cytometry analysis on BD FACS  software.  
 
 
3.4. Characterization of CD177 Counter receptor by immunoblot 
 
To determine the counter receptor of CD177 on endothelial cells, an immunoblot 
with endothelial cell lysates and CD177-Fc fusion protein was performed. 
Aliquots of 20μg of cell lysates were separated on SDS-PAGE under 
nonreducing conditions after blotting the membrane was stained with CD177-Fc 
and peroxidase labelled RAH IgG (Figure 10). Fc alone failed to detect any 
proteins from EC lysate. Interestingly, CD177-Fc reacted with 130 KDa 
endothelial protein. In the control experiments, the expression of PECAM-1 could 
be demonstrated by staining with Gi18 specific for PECAM-1. No reaction with 
anti-CD177 on endothelial cells could be detected with mab 7D8.  
 
 
 
Figure 10: Immunoblotting analysis of HUVEC lysates with CD177-Fc fusion protein. Cell lysates 
were separated on 8% SDS-PAGE under nonreducing conditions. Separated proteins were then 
transferred onto PVDF membrane and incubated with Fc alone, CD177-Fc, anti-PECAM-1 (mab 
Gi18) and anti-CD177 (mab 7D8). Bound proteins were labelled with peroxidase labelled RAH 
IgG or RAM IgG and ECL detection system. 
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3.5. Analysis of CD177 counter receptor by ELISA 
 
ELISA was performed to confirm the interaction between CD177 and PECAM-1. 
For this purpose, CD177-Fc was immobilized on to microtiter wells coated 
donkey anti-human IgG. After the washings, lysates of HUVEC was added and 
bound protein was screened with mabs against E-selectin, P-selectin, and 
PECAM-1 and then detected with peroxidase labeled secondary antibody and 
OPD as substrate (Figure 11). A higher reaction was detected when anti 
PECAM-1 was applied in comparison to anti-E-selectin and anti-P-selectin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Antigen capture assay to find the CD177-Fc counter receptor.  
Microtiter plates were coated with DAH IgG bound to CD177, followed by the addition of HUVEC 
cell lysates. Subsequently mabs against E-selectin, P-selectin, and PECAM-1 were added and 
followed by incubation with peroxidase labeled DAM IgG. Bound antibodies were then visualized 
by the addition of OPD substrate. Optical density was measured on ELISA reader at 492 nm. The  
data is the representative of the mean+SD (p<0.05) of two independent experiments. 
 
 
3.6. Determination of CD177-Fc counter receptor by immuprecipitation and 
 immunoblotting  
 
To characterize the CD177 counter receptor further, we performed 
immunoprecipitation with biotin surface labelled HUVEC and CD177-Fc and Fc 
alone as control. The immunoprecipitates were then separated on 8% SDS-
PAGE under nonreducing conditions and transferred onto a membrane for 
analysis with peroxidase labelled anti-human IgG and chemiluminescence 
system. As shown in figure 13, CD177-Fc fusion protein precipitated a protein 
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with respective Mr of 130 kDa. This result is in accordance to our previous finding 
using immunoblot (see figure 10).   
We then performed a combination of immunoprecipitation and immunoblot to 
identify this 130 kDa. Biotin labelled HUVEC cells were lysed, and then 
immunoprecipitated with CD177-Fc. Immunoprecipitates were run on a 8%SDS-
PAGE under nonreducing conditions and analysed in immunblot using different 
mabs. When immunoblotting was performed with Gi18 against PECAM-1, a 
positive reaction was observed. Contrary, no reaction was detected when 
immunoprecipitation was done with Fc alone. Furthermore, no reactions were 
detected with mabs against E- and P-Selectin. 
These results strongly indicated that endothelial PECAM-1 represents the 
counter receptor of CD177. 
 
Figure 12:  Immunoprecipitation analysis of biotinylated human endothelial cells.  
Biotin labelled cell lysates were precipitated with control Fc and CD177-Fc and run on 8% SDS-
PAGE under nonreducing conditions. Immunoprecipitates were then blotted to PVDF membrane 
and detected with streptavidin conjugated horseradish peroxidase and ECL system. 
Immunoprecipitation and immunoblotting for the identification of CD177 counter receptor. Lysates 
of HUVEC were immunoprecipitated with control Fc and CD177-Fc stained with streptavidin HRP 
(lanes 1, 2). After blotting, PVDF membrane was stained with mouse IgG (as control; lanes 3, 4), 
mab Gi18 (anti-PECAM-1; lanes 5, 6), mab CD62 E (anti E-Selectin ; lanes 7, 8), and mab CD62 
P (anti-P-Selectin; lanes 9, 10).  
 
 
3.7. Analysis of CD177-Fc binding to PECAM-1 transfected Cells 
 
To confirm these findings, the binding of CD177-Fc to L-cells transfected with 
PECAM-1 was analysed by flow cytometry (Figure 13). Panel A shows the 
expression of PECAM-1 on transfected cells by the use of mab Gi18 against 
PECAM-1. In the control experiment with isotype IgG no staining was observed. 
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When CD177-Fc was analysed with these cells a positive reaction could be 
detected (panel B). In the control experiment, Fc alone did not show any binding, 
whereas PECAM-Fc reacted with PECAM-1 transfectant in homophilic manner 
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Figure 13: Binding of CD177-Fc to PECAM-1 transfected cells in flow cytometry. A) PECAM-1 
transfected cells were incubated with mouse IgG (as control) or mab Gi18 against PECAM-1. 
Antibody binding was detected with fluorescein labelled secondary antibody and analysed by flow 
cytometry. B) PECAM-1 transfected cells were incubated with CD 177-Fc (left panel) or PECAM-
1 Fc (right panel). Binding of Fc fusion proteins were then analysed on flow cytometry. 
 
 
To confirm our finding that PECAM-1 binds to CD177, PECAM-1 transfected cells 
were surface labelled with biotin and subjected to immunoprecipitation with 
CD177-Fc and PECAM Fc fusion proteins (Figure 14). Fc alone was run in 
parallel. Again, CD177-Fc precipitated specifically a 130 KDa band. Similar band 
could be precipitated with PECAM-Fc fusion protein.  
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Figure 14: Immunprecipitation of biotinylated HUVEC with Fc alone (lane 1), PECAM-Fc (lane 2) 
and CD177-Fc (lane 3) under nonreducing conditions on 8% SDS PAGE. Immunprecipitates 
were detected with horseradish peroxidase labelled streptavidin and ECL system.  
 
 
3.8. Analysis of CD177 and PECAM-1 Interaction by SPR  
 
We sought to analyse the CD177 and PECAM-1 protein-protein interaction 
directly in SPR technology. For SPR analysis, CD177 were purified from 
neutrophils of healthy blood donors by affinity chromatography. Soluble 
recombinant PECAM-1 proteins were produced from a cell line transfected with 
PECAM-1 (a gift from Dr. Newman, Milwaukee, USA). The purity of both proteins 
could be demonstrated by silver staining analysis and immunoblotting (Figure 
15).  
 
 
 
Figure 15: Analysis of purity of recombinant proteins, purified CD177 (left panel) and PECAM-1 
(right panel) proteins were analysed by silver staining and immunoblottting using mab 7D8 (anti-
CD177) or mab Gi18 (anti-PECAM-1), respectively. 
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SPR is the real time evaluation of protein interactions demonstrated the direct  
interaction between CD177 and PECAM-1. The obtained sensogram readings 
were plotted as response units (RU). 
For SPR analysis, the purified PECAM-1 protein was immobilized to the sensor 
chip, and the binding of CD177 (heterodimer) and PECAM-1 (homodimer) was 
tested. Real-time protein-protein interaction was recorded as resonance units. 
Sensograms were plotted and aligned (Figure 16). When 2 µM of soluble CD177 
was injected, specific association occurred reaching a maximum after 30 sec. 
This CD177-PECAM-1 complex dissociated after stopping the flow of CD177 
ligand. In contrast, no interaction was detected when the control protein was 
injected (Figure 17a). To compare the affinity of heterophilic and homophilic 
interactions, binding of PECAM-1 to PECAM-1 was analyzed. As shown in Figure 
17b, PECAM-1 bound to PECAM-1 with weak affinity as compared with CD177. 
These results indicated that PECAM-1 may bind preferentially heterophilic 
partner.  
 
 
Figure 16: Brief illustration of SPR components. 
L:light source, D:photoiodide array, P:Prism, S:Sensor surface, F:Flow cell, t1&t2:resonance 
phenomenan time course, CD177: Human neutrophil antigen-2, PECAM-1: Platelet Endothelial 
Cell Adhesion Molecule. 
 
Our next assessment was to check which mutation is involved in PECAM-1 
heterophilic interaction to CD177. For this purpose the mutant PECAM-1 was 
immmobilized on sensor chip and repeated the injection of 2µM concentration of 
soluble CD177 along with wild type PECAM-1. The sensogram obtained 
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represents the impaired interaction of mutant PECAM-1 to CD177 measured by 
association and dissociation phases. The examination with PECAM-1 mutant (K 
89 A - point mutation on first IgG domain of PECAM-1), showed the interaction is 
partially inhibited  the interaction between CD177 and PECAM-1, which indicated 
that its not to exclude the possibility of domain 1 also to be invoved with 
heterophilic binding or resides close to the domain involved.  
 
 
 
Figure 17: a) Schematic representation of CD177-PECAM-1 interaction represented as response 
units in SPR method analysed by real-time association and dissociation of CD177-PECAM-1 
proteins measured and recorded on sensogram. 
b) Illustration of heterotypic CD177-PECAM-1 and homotypic PECAM-1-PECAM-1 interaction 
demonstrated by surface plasmon resonance assay of realtime interaction of purified 
protein assay graph recorded on sensogram connected to biacore machine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Examination of mutation on PECAM-1 domain-1 affects the interaction between 
CD177-PECAM-1. Sensogram real time-graph represent the response units, PECAM-1 (Wt) 
interaction to CD177 (Blue), PECAM-1 (mutant) interaction to CD177. 
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3.9. Adhesion of CD177 transfected Cells to PECAM-1 
 
To analyse whether CD177-PECAM-1 interaction plays a role in cell adhesion, 
we tested the adhesion capacity of CD177 transfected U937 cells on immobilized 
PECAM-1 assay in comparison to nontransfected U937 cells. As shown in the 
Figure 19, CD177 transfected U937 cells bound stronger to immobilized PECAM-
1 than nontransfected U937 cells. Inhibition studies were then applied to confirm 
the specificity of this interaction. Mab MEM166 against CD177 inhibits almost 
70% of the cell adhesion while the other CD177 specific mab 7D8 blocked 30% 
of the adhesion. Our epitope mapping study by the use of biotinylated 7D8 and 
unlabelled MEM-166 in flowcytometry showed that both mabs reacted against 
different epitopes on CD177 (data not shown). Significantly, purified CD177 
protein inhibits the CD177-PECAM-1 interaction completely, almost to the basal 
levels as observed with PBS as control.  
Similar inhibition was observed with mabs against PECAM-1. Among different 
PECAM-1 specific mabs, PECAM1.2 and PECAM1.1 showed inhibitory capacity 
of 50% and 40%, respectively, where as mab Gi18 did not show any inhibition 
potential. Epitope mapping studies of mabs in the past (David et al, 1998; Sun et 
al, 1996) demonstrated that PECAM1.1 and 1.2 are situated on domains 5, 6 of 
PECAM-1 molecule. In contrast, the epitope of mab Gi18 is located on domain 1. 
These results indicated that CD177 binds the carboxy terminal region of PECAM-
1 located on domains 5, 6. 
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Figure 19: Binding of CD177 transfected U937 cells to immobilized PECAM-1 and inhibition  
by specific monoclonals against CD177 and PECAM-1. 
1. Binding of CD177 transfected cells to PBS control 2. CD177 3. 7D8 4. MEM-166 5. s CD177, 
6. Gi 18, 7. Gi 34.  8, 9, 10. PECAM 1.1, PECAM 1.2, PECAM 1.3 respectively, inhibition of 
CD177 transfected U937 to PECAM-1 was demonstrated with panal of mabs against CD177 as 
well as against PECAM-1(3-10).  
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4. DISCUSSION 
 
Neutrophils are the primary phagocytes involved in the defense against 
pathogens during the inflammatory response. The proinflammatory cytokines and  
chemotactic factors signal the recruitment of neutrophils to the sites of infection 
by a multistep process called diapedesis. Since CD177 is a specific neutrophil 
antigen that is upregulated during bacterial infection, we asked the question 
whether CD177 is crucial for neutrophil endothelial interaction.  
 
To achieve this goal we produced the CD177-Fc fusion protein by recombinant 
technology. CD177-Fc is a bivalent immunoadhesive molecule which provides 
higher affinity in comparison to the CD177 monomer. Studies in the past 
demonstrated that such immunoadhesive molecules represent a useful tool for 
capturing the ligand or counter receptor (Kato et al, 1992; Lino et al, 2005). By 
expression in the insect cell system we were able to produce immunoreactive 
CD177-Fc. Analysis with endothelial cells showed that this protein reacted with 
the endothelial protein of 130 kDa. Further immunochemical characterization by 
the use of immunoprecipitation and immunoblotting showed that endothelial 
PECAM-1 turn to the counter receptor for CD177. This result was confirmed by 
the direct protein-protein analysis using SPR technology.  
 
One of the challenging areas in immunology is search for the ligand-receptor 
interaction. The past few years have seen an increase in methodology and 
instrumentation focused on the ability to discover and characterize the putative 
receptor-ligand pairs. Nowadays, a variety of powerful technology is now 
available to evaluate biospecific interactions. Significant advances have been 
made in this area, one of the widely used is the SPR biosensor chip (Piehler et 
al, 2005; Pattnaik et al, 2005; Gurbaxani et al, 2006) based assay to demonstrate 
direct protein-protein interaction in real time. In general, this novel technique 
allows the analysis of protein-protein interaction with minute amount of protein. In 
this study we could demonstrate by SPR analysis that the direct specific 
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interaction between CD177 and PECAM-1 (heterophilic manner) is stronger than 
the interaction between PECAM-1 and PECAM-1 (homophilic manner).  
 
In line with these findings, the CD177-Fc fusion protein bound specifically to the 
PECAM-1 transfected L-cells. Immunoprecipitation analysis showed that the 
PECAM-1 could be pulled down from the PECAM-1 transfectant by the CD177-
Fc.  
 
To study the relevance of CD177 in a neutrophil adhesion, we tested the 
adhesion capacity of the U-937 monocytic cell lines expressing CD177. Using 
this transfected cells, we could demonstrate specific adhesion of these cells onto 
immobilized PECAM-1 and this cell adhesion could be blocked specifically with 
mabs against CD177 and against PECAM-1, which recognized the last two Ig 
domains (domains 5 and 6) of PECAM-1. In contrast, mabs against the first two 
Ig domains (domains 1 and 2) of PECAM-1 failed to block the adhesion of CD177 
transfected cells on PECAM-1. These results strongly suggested that the 
domains 5 and 6 of PECAM-1 are responsible for the CD177 binding. Studies in 
the past described that these two domains were involved in the L-cells mediated 
heterophilic aggregation (Yan et al, 1995). However, the counter-receptor of 
PECAM-1 in this process was not known. 
 
Simultaneous inhibition with the panel of monoclonal antibodies and soluble 
CD177 provides cumulative evidence for the existence of CD177-PECAM-1 
interaction. Neutrophils carry PECAM-1 on their surface and known to interact 
with endothelial PECAM-1 (trans-interaction) mediate leukocyte transendothelial 
migration, their engagement activate or regulate the expression of integrins and 
its heterophilic adhesion receptor of αvβ3 (Dangerfield et al 2002). neutrophilic 
PECAM-1 augment neutrophil signal transduction, integrin activation, and 
transmigration in a stimulus-specific manner, neutrophilic PECAM-1 may activate 
other adhesive protein(s) by cis-interaction also to modulate the cytoskeleton 
activity of neutrophils. 
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Until today little is known about the impact of PECAM-1 on neutrophils in the 
adhesion and transendothelial migration process (Muller et al, 1995; Berman et 
al, 1995) density of PECAM-1 molecules on leukocytes was very low to support 
PECAM-1 homophilic interactions (Liao et al, 1999; 1997). 
 
Transgenic mice (Fang Liao et al, 1999) constitutively expressing PECAM-1 was  
attempted to study PECAM-1 role in chronic inflammation, mice that produced 
moderate concentrations of PECAM-1-IgG demonstrated a severely blunted 
acute inflammatory response, in the same model mice that produced higher 
concentrations of PECAM-1 (400-1000 μg/ml) concentrations were unresponsive 
to its anti inflammatory effects,in this model PECAM-1-IgG blocks the PECAM-1 
dependent interaction demonstrated the importance of PECAM-1 in inflammation, 
also its observed that anti-PECAM-1 reagents fail to block the transmigration of 
leukocytes 100%, some residual transmigration observed in several acute 
inflammatory models and in PECAM-1 knockout mice, this 10-20% of residual 
transmigration is postulated to be dependent on PECAM-1 independent routes of 
transmigration. Hence this transgenic mouse serves to study the anti-
inflammatory model targeting PECAM-1. Muller et al, succeded in their attempt to 
block transmigration of neutrophils, monocytes, NK cells in acute inflammation by 
the use of mab against PECAM-1 or soluble recombinant PECAM-IgG.  
 
Study in PECAM-1 deficient mice showed that PECAM-/- neutrophils are much 
less polarized and spreading in response to IL-8 gradient, indicating that 
PECAM-1 on neutrophils has a major role in modulating neutrophil-directed 
migration (Wu et al, 2005). Neutrophil and monocyte migration in response to 
inflammatory stimuli in PECAM-1 deficient mice study indicating neutrophil 
PECAM-1 importance in the transmigration of neutrophils (Schenkel et al, 2004). 
PECAM-1 deficient mice also demonstrate it role as inhibitory receptor in 
autoimmune arthritis model to suppress collagen-induced arthritis (Mae-xhum 
wong et al, 2005). Schenkel et al (2006) work on PECAM-1 deficient mice strain 
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in acute inflammation model demonstrates PECAM-1 dependent and PECAM-1 
independent mechanisms in acute inflammation. 
 
It is known that PECAM-1 can interact with PECAM-1 in a homophilic manner 
(Cindy et al, 2000). However, this direct adhesive interaction is debated, because 
PECAM-1 seems to preferentially act as a signaling molecule, which can 
modulate endothelial functions by up regulating integrins (Thompson et al, 2001) 
and down regulate E-selectin (Litwin et al, 1997) rather than act as a mediator of 
homophilic adhesion.  
 
Stockinger et al (1990) demonstrated that PECAM-1 can be down regulated after 
activation of granulocytes. Similar phenomenon was observed during the 
granulocytes maturation as well as in the lymphocytes (Lund-Johansen et al, 
1993; Wedle et al, 1999). This is in accordance to our observation by the SPR 
which demonstrated that PECAM-1 bounds weakly to PECAM-1.  
 
Recently, Göhring et al (2004) described that the CD177 surface expression is 
enhanced in patients with bacterial infections, polycythemia rubra vera and 
neutrophils of G-CSF stimulated donors compared with healthy donors. Further 
investigation is necessary to address the question of whether or not the activation 
of neutrophils leads to upregulation of CD177 surface expression is associated 
with the modulation of PECAM-1 binding capacity. . 
 
Furthermore, there is evidence that suggests that PECAM-1 can also interact in a 
heterophilic manner. Several of the counter receptors for this interaction were 
described (Buckley et al, 1996; Delisser et al, 1993). One of the most described 
counter receptor for PECAM-1 is αvβ3 (Piali et al, 1995; Wong et al, 2000; Chiba 
et al, 1999). The αvβ3 is known as a receptor for the vitronectin, which is 
expressed on endothelial cells, neutrophils, and other blood cells (Piali et al, 
1995). Since endothelial cells and neutrophils, both carry αvβ3 as well as 
PECAM-1, it is difficult to dissect the specific partner for each receptor; e.g 
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endothelial PECAM-1 could theoretically interact with PECAM-1 or αvβ3 on 
neutrophils. In addition, such an interaction was not demonstrated on the borders 
of the endothelial cells, where PECAM-1 is expressed in high density (Thompson 
et al, 2000). Furthermore, this effect may also be caused by the activation of 
αvβ3 integrin indirectly by coupling of PECAM-1/PECAM-1 (cis-interaction) 
(Cindy et al, 2000). In comparison to αvβ3, CD177 is solely expressed on 
neutrophils but not on endothelial cells. 
 
Thus, the specific interaction between CD177 and the endothelial PECAM-1 was 
evident.  Based on the observation that the homophilic interaction between the 
neutrophil PECAM-1 and endothelial PECAM-1 is much weak, we are 
substantiated in  proposing that the heterophilic CD177-PECAM-1 binding is an  
important neutrophil-endothelial interaction, which may crucial for the neutrophil 
adhesion and migration through endothelial barrier. 
 
Neutrophils are the prime leukocytes involved in innate immunity. CD177 is 
exclusively expressed on neutrophils with proven interaction to endothelial 
PECAM-1 constitute the innate immune response against host during bacterial 
infection and sepsis.  
 
In recent years studies focussed to reveal neutrophils role in adaptive immunity 
(Puellmann et al ;BA Maletto et al, 2006) as neutrophils are known to express T 
cell receptor and costimulatory molecules (CD86 and CD80). PECAM-1 is known 
to express on transformed cells as in breast carcinoma and giloma (Charpin et al 
1995; Aroca et al, 1999; Tang et al, 1994). Thus CD177 may play a role in cancer 
by interacting with PECAM-1 as a target cell either as positive or negative 
stimulator. One may also speculate that CD177 ligand binding may activate the 
neutrophils as effector cells to produce cytokines and to help the maturation of 
other cells as antigen presenting cells and T lymphocytes. 
 
                                                                                                                                                                       
                                                                                                      
55
Recent study demonstrated that uPAR (Kim et al, 2007), which showed structural 
homologous with CD177, inhibits the growth of malignant glioma (Kim et al, 2007 
So far number of receptors simultaneously interacting with multiple ligands or 
counter receptors has been described; JAM (Keiper et al, 2005) is one of an 
example for such interaction(s). 
 
Our understanding and finding that CD177 serve as a counter receptor for 
PECAM-1 and the ability of CD177/PECAM-1 interactions to mediate neutrophil 
transendothelial migration suggest that this system may specifically mediate 
neutrophil transmigration under specific conditions. 
Thus, PECAM-1-CD177 interaction may represent an alternative mechanism for 
the neutrophil transmigration in certain activation conditions (bacterial infection, 
sepsis etc). In conclusion, we have identified a heterophilic binding partner of 
endothelial PECAM-1. Thus, it represents a challenging new approach to our 
understanding of neutrophil/endothelial cell interplay in host defence. 
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5. SUMMARY 
 
This study sheds light on the characterisation of CD177 and identification of 
CD177s counter receptor on endothelium. We could demonstrate that PECAM-1 
on endothelial cells functions directly as the counter receptor for CD177 by 
following observations; 
 
1. Our recombinant CD177-Fc fusion protein, which was produced in insect cells, 
reacted with 130 KDa molecules on endothelium. 
2. Screening with different mabs identified the 130 KDa protein as endothelial 
PECAM-1.  
3. Biochemical and immunological studies using recombinant CD177-Fc fusion 
protein confirmed that endothelial PECAM-1 functions directly as the counter-
receptor for CD177. 
4. Functional studies in vitro demonstrated that purified CD177 protein inhibits  
CD177 mediated cell adhesion to immobilized PECAM-1 protein as well as 
neutrophil migration through endothelial cells. 
 
These results indicate that CD177 can act as cell adhesion molecule involving 
neutrophil-endothelial interaction. This observation may provide a new concept in 
understanding the multi-step process of transendothelial migration. 
In the future, this concept should be studied in different in vitro as well as in vivo 
model in more detail.  
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6. PROSPECTIVE STUDY: 
 
Further indepth study needed to evaluate the implicated role played by 
inhibiting and activating anti-CD177 as well as anti-PECAM-1 in modulating 
multi step neutrophil transmigration in conditions of chronic inflammation. 
To study the physiological importance of CD177 expression on neutrophils and  
its interaction to endothelium by studying Geneknock out or SiRNA at protein 
level.  
To investigate whether any possible role plays by CD177 to extracelular matrix-
proteins 
To examine if at all any potential role played by CD177 during different patho 
physiological conditions as in diseases of atherogenesis, diabetes and cancer 
metastasis. 
To study the significance of CD177 in haematopoietic stage expression. 
Furthermore, to study therapeutic intervention aiming CD177-PECAM-1 
interaction to prevent organ failure and multi consequences in the development 
of sepsis, to study the anti-inflammatory efficacy of soluble recombinant CD177 
or mabs against CD177 in inflammation model.   
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6. ABBREVIATIONS 
APS-Ammonium Persulphate 
BSA-Bovine Serum Albumin 
BCA- Bi Cinchoninic Acid 
CD-Clustar of Differentiation 
CML-Chronic Myelogenous Leukaemia 
CHO-Chineese Hamster Ovary cells 
Deg C-Degree celcius 
DMSO- Dimethyl sulfoxide 
DTT-1,4-dithiothreitol. 
EDTA-Ethylene Diamine Tetra Aceticacid 
ELISA-Enzyme Linked Immunosorbant Assay. 
FBS-Fetal Bovine Serum 
FACS-Flourescence Activated Cell Sorting 
FITC- Fluorescein Iso Thiocyanate 
GABA-Gama Amino Butyricacid 
G-CSF-Granulocyte Colony Stimulating Factor 
GPI-Glycosyl phosphotidyl inositol 
HLA-Human leukocyte antibodies 
HAT-Hypoxanthin-aminopterin conjugate 
HCl-Hydrochloric acid 
HRP-Horse Radish Peroxidase 
HNA 2a-Human Neutrophil Antigen 2a 
HUVEC-Human Umbilical Vein Endothelial Cells 
ISBT-International Society of Blood Transfusion 
IPB-immuno Precipitation Buffer 
Ly-6-Leucocyte antigen family 
Mab-Monoclonal antibody 
MPD- Myelo Proliferative Disoorders 
mts- Minutes 
ngm-Nano gram 
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NaCl-Sodium chloride 
NaOH-Sodium chloride 
NK-Natural Killer Cells 
OPD-Ortho phenylene diamine.  
PBS-Phosphate buffer saline 
PEG-Poly ethylene glycol 
PFA-Para formaldehyde 
PRV-1-Polycythemia Rubra Vera 
PMSF- Phenyl Methyl Sulphonyl Fluoride 
p/s-penicillin-streptomycin 
PVDF- Polyvinylidenfluorid 
SPR-Surface Plasmon Resonance 
RBC-Red Blood Carpescules 
RT-Room Temperature 
rpm-revolutions per minute 
SDS-PAGE-Sodium Dodecyl Sulphate-Polyacrylamide Gel 
SNP-Single Neucleotide Polymorphism 
TBS-Tris Buffer Saline 
TEMED-Tetra-Methyl Ethylene Diamine 
TRALI-Transfusion Related Acute Lung Injury 
Triton X-100 (t-octylphenoxypolyethoxyethanol) 
uPAR-Urokinase Plasminogen Activating Receptor 
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